Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, California. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, ...

Copyright held by the owner/author(s).

The development of second-generation covalent “off”-state KRAS G12C inhibitors is taking off. Two candidates, D3S-001 and divarasib, highlighted at the 2024 ESMO Congress, show better efficacy, with ...

Major Finding: Glioblastoma cells recruit hybrid dendritic cell–like neutrophils to suppress tumor growth. Concept: Myeloid precursors from skull marrow differentiate within tumors to promote an ...

University of Arkansas for Medical Sciences, Little Rock, AR, United States ...

Healthcare services company Cardinal Health will acquire Integrated Oncology Network (ION) for about $1.12 billion. A physician-led operator of community cancer centers, ION includes more than 50 ...

Search for other works by this author on: ...

Major Finding: Agonism of gasdermin D (GSDMD) triggers pyroptosis in cancer cells and inhibits tumor growth. Concept: The efficacy of the GSDMD agonist, DMB, is dependent on tumor cell GSDMD ...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...

The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...